Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21382056 | 1.00 | OPRD1 (0.53) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21382026 | 1.00 | OPRD1 (0.53) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30149800 | 1.00 | OPRD1 (0.53) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7329909 | 0.98 | OPRD1 (0.52) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7319671 | 0.93 | SLC6A2 (0.45) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL9768345 | 0.91 | SLC6A2 (0.46) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2247018 | 0.89 | OPRD1 (0.57) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL23211912 | 0.89 | OPRD1 (0.54) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL3657538 | 0.87 | OPRD1 (0.56) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| Oxalic Acid SCHEMBL7329503 | 0.87 | OPRD1 (0.51) | OPRD1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0242687-A2 | Process for the preparation of 1-aryl-5-amino-pyrazoles | BAYER AG (DE) | 1987-10-28 | — | — | EP | claimed |
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-11420961-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
| CN-111936503-A | Oxazin monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-111386269-A | Novel heterocyclic compound | 豪夫迈·罗氏有限公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | disclosed |
| EP-2390248-A1 | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies | FAES FARMA, S.A. (ES) | 2011-11-30 | — | — | EP | disclosed |
| CN-1058780-A | Has the active thiazolidine carboxylic acid amides derivative of anti-allergy, their preparation and application | SANKYO CO (JP) | 1992-02-19 | — | — | CN | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4810713-A | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0242687-A2 | Process for the preparation of 1-aryl-5-amino-pyrazoles | BAYER AG (DE) | 1987-10-28 | — | — | EP | disclosed |
| EP-0235463-A2 | N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-09-09 | — | — | EP | disclosed |
| US-4032642-A | SEDATIVES, TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-06-28 | — | — | US | disclosed |
| US-3956296-A | ANTIINFLAMMATORY, SEDATIVES, TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | OPRD1 2016/4885SLC6A2 4783/4885SLC6A4 4841/4885 |
| US-11420961-B2 | Heterocyclic compounds | LPXN, MLX, CCNY | OPRD1 1395/4885SLC6A2 4377/4885SLC6A4 4397/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | OPRD1 2016/4885SLC6A2 4783/4885SLC6A4 4841/4885 |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | LPXN, MLX, CCNY | OPRD1 1395/4885SLC6A2 4377/4885SLC6A4 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.